Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69


Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.

Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O.

Expert Rev Vaccines. 2017 Sep;16(9):883-894. doi: 10.1080/14760584.2017.1357471. Epub 2017 Jul 27. Review.


Seroprevalence study of Toscana virus and viruses belonging to the Sandfly fever Naples antigenic complex in central and southern Italy.

Marchi S, Trombetta CM, Kistner O, Montomoli E.

J Infect Public Health. 2017 Nov - Dec;10(6):866-869. doi: 10.1016/j.jiph.2017.02.001. Epub 2017 Feb 23.


Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?

Trombetta C, Piccirella S, Perini D, Kistner O, Montomoli E.

Vaccines (Basel). 2015 Mar 18;3(1):172-85. doi: 10.3390/vaccines3010172. Review.


Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients.

Fritz R, Hetzelt N, Ilk R, Hohenadl C, van der Velden MV, Aichinger G, Portsmouth D, Kistner O, Howard MK, Barrett PN, Kreil TR.

Open Forum Infect Dis. 2014 Aug 25;1(2):ofu072. doi: 10.1093/ofid/ofu072. eCollection 2014 Sep.


Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

Wodal W, Schwendinger MG, Savidis-Dacho H, Crowe BA, Hohenadl C, Fritz R, Brühl P, Portsmouth D, Karner-Pichl A, Balta D, Grillberger L, Kistner O, Barrett PN, Howard MK.

PLoS One. 2015 Feb 26;10(2):e0113963. doi: 10.1371/journal.pone.0113963. eCollection 2015.


Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.

Aichinger G, Grohmann-Izay B, van der Velden MV, Fritsch S, Koska M, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Clin Vaccine Immunol. 2015 Jan;22(1):46-55. doi: 10.1128/CVI.00275-14. Epub 2014 Oct 29.


Superior in vitro stimulation of human CD8+ T-cells by whole virus versus split virus influenza vaccines.

Halbroth BR, Heil A, Distler E, Dass M, Wagner EM, Plachter B, Probst HC, Strand D, Hartwig UF, Karner A, Aichinger G, Kistner O, Landfester K, Herr W.

PLoS One. 2014 Jul 29;9(7):e103392. doi: 10.1371/journal.pone.0103392. eCollection 2014.


Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population.

van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G.

J Infect Dis. 2014 Jan 1;209(1):12-23. doi: 10.1093/infdis/jit498. Epub 2013 Sep 16.


Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Smith LR, Wodal W, Crowe BA, Kerschbaum A, Bruehl P, Schwendinger MG, Savidis-Dacho H, Sullivan SM, Shlapobersky M, Hartikka J, Rolland A, Barrett PN, Kistner O.

Hum Vaccin Immunother. 2013 Jun;9(6):1333-45. doi: 10.4161/hv.24209. Epub 2013 Mar 6.


Lack of innate interferon responses during SARS coronavirus infection in a vaccination and reinfection ferret model.

Cameron MJ, Kelvin AA, Leon AJ, Cameron CM, Ran L, Xu L, Chu YK, Danesh A, Fang Y, Li Q, Anderson A, Couch RC, Paquette SG, Fomukong NG, Kistner O, Lauchart M, Rowe T, Harrod KS, Jonsson CB, Kelvin DJ.

PLoS One. 2012;7(9):e45842. doi: 10.1371/journal.pone.0045842. Epub 2012 Sep 24.


Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN.

Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8.


A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory.

Loew-Baselli A, Pavlova BG, Fritsch S, Poellabauer EM, Draxler W, Kistner O, Behre U, Angermayr R, Neugebauer J, Kirsten K, Förster-Waldl E, Koellges R, Ehrlich HJ, Barrett PN.

Vaccine. 2012 Sep 7;30(41):5956-66. doi: 10.1016/j.vaccine.2012.07.039. Epub 2012 Jul 28.


A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.

Sabarth N, Savidis-Dacho H, Schwendinger MG, Brühl P, Portsmouth D, Crowe BA, Kistner O, Barrett PN, Kreil TR, Howard MK.

Vaccine. 2012 Aug 10;30(37):5533-40. doi: 10.1016/j.vaccine.2012.06.043. Epub 2012 Jun 29.


A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.

Wodal W, Falkner FG, Kerschbaum A, Gaiswinkler C, Fritz R, Kiermayr S, Portsmouth D, Savidis-Dacho H, Coulibaly S, Piskernik C, Hohenadl C, Howard MK, Kistner O, Barrett PN, Kreil TR.

Vaccine. 2012 Jun 29;30(31):4625-31. doi: 10.1016/j.vaccine.2012.04.102. Epub 2012 May 10.


Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1.


A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.

Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN.

Clin Infect Dis. 2012 Apr;54(7):946-54. doi: 10.1093/cid/cir959. Epub 2012 Jan 19.


Clinical development of a Vero cell culture-derived seasonal influenza vaccine.

Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN.

Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13.


A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies.

Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR.

J Infect Dis. 2012 Jan 1;205(1):28-34. doi: 10.1093/infdis/jir711. Epub 2011 Nov 16.


Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.

Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ.

Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12.


Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.

Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN.

Vaccine. 2011 Nov 21;29(50):9376-84. doi: 10.1016/j.vaccine.2011.09.125. Epub 2011 Oct 12.


Supplemental Content

Loading ...
Support Center